Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

264.92
+1.410.53%
Post-market: 265.050.1300+0.05%19:47 EDT
Volume:417.85K
Turnover:110.05M
Market Cap:17.54B
PE:20.44
High:265.50
Open:265.00
Low:260.00
Close:263.52
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.74
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:10.59
PE(LYR):-59.97

Loading ...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Moderna (MRNA) and Stevanato Group (STVN)

TIPRANKS
·
Aug 03

Ascendis Pharma A/S Expected to Post Earnings of €1.38 a Share - Earnings Preview

Reuters
·
Aug 03

Ascendis Pharma is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 24

Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong

Simply Wall St.
·
Jul 12

Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says

MT Newswires Live
·
Jul 09

Wedbush Raises Price Target on Ascendis Pharma to $327 From $273, Keeps Outperform Rating

MT Newswires Live
·
Jul 09

Ascendis Pharma A/s : Wedbush Raises Target Price to $327 from $273

THOMSON REUTERS
·
Jul 09

Ascendis Pharma Releases Week 104 Approach Trial Radiographic Data Presentation on Transcon CNP in Achondroplasia

Reuters
·
Jul 09

European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading

MT Newswires Live
·
Jul 08

Barclays Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
Jul 08

Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data

Simply Wall St.
·
Jul 04

14 Value Stocks of Companies Primed for Rapid Growth Through 2028

Dow Jones
·
Jul 02

Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial

TIPRANKS
·
Jun 30

Ascendis Says Transcon CNP Achondroplasia Trial Shows Continued Leg-alignment Gains at Week 104

Reuters
·
Jun 30

Ascendis Pharma Added to Multiple Russell Indexes

MT Newswires Live
·
Jun 27

Ascendis Pharma Reports Week 104 Approach Trial Data Showing Improved Leg Alignment with Transcon CNP in Achondroplasia

Reuters
·
Jun 26

Movement Alert|Ascendis Pharma Rises 8.3% in Regular Trading, Core Drug Long-Term Clinical Data Impresses as Analysts Reiterate Bullish Stance

Market Focus
·
Jun 26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Jun 18

Ascendis Pharma sells priority review voucher for $187.5 million cash

Reuters
·
Jun 18

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

TIPRANKS
·
Jun 17